The particle has landed-characterizing the fate of inhaled pharmaceuticals

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue SUPPL. 2, 2010, Pages

  Patton, John S ^a   Brain, Joseph D ^b   Davies, Lee A ^c   Fiegel, Jennifer ^d   Gumbleton, Mark ^e   Kim, Kwang Jin ^f   Sakagami, Masahiro ^g   Vanbever, Rita ^h   Ehrhardt, Carsten ⁱ  

^a Dance Pharmaceuticals   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF IOWA   (United States)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

ⁱ TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

aerosol deposition; drug absorption; gene delivery; lung clearance; lung disease; macrophages; particle dissolution; peptides; proteins; pulmonary pharmacokinetics; RNAi

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CHORIONIC GONADOTROPIN; FLUTICASONE PROPIONATE; GLYCOPROTEIN P; HUMAN GROWTH HORMONE; IMMUNOGLOBULIN G; INSULIN; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER; PEPTIDE TRANSPORTER 1; PLASMID DNA;

ACUTE LUNG INJURY; AEROSOL; ANTIGEN PRESENTING CELL; ARTICLE; ASPERGILLOMA; BLOOD BRAIN BARRIER; CELL TRANSPORT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TRANSPORT; EPITHELIUM CELL; GENE THERAPY; GENE TRANSFER; GLYCOSYLATION; HUMAN; HYDROPHOBICITY; IMAGING; LUNG; LUNG ALVEOLUS; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG CLEARANCE; LUNG DEPOSIT; LUNG FIBROSIS; LUNG GRANULOMA; MACROMOLECULE; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PATHOPHYSIOLOGY; PNEUMONIA; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PULMONARY HYPERTENSION; RESPIRATORY SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPPER RESPIRATORY TRACT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG DELIVERY SYSTEMS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LUNG; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 78650225640     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0836     Document Type: Article

References (136)

1. Brain JD, and Valberg PA: Deposition of aerosol in the re-spiratory tract. Am Rev Respir Dis. 1979;120:1325-1373.
2. Patton JS, and Byron PR: Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67-74.
3. Watson AY, and Brain JD: Uptake of iron-oxide aerosols by mouse airway epithelium. Lab Invest. 1979;40:450-459.
4. Schürch S, Gehr P, Im Hof V, Geiser M, and Green F: Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol. 1990;80:17-32.
5. Leith DE, Butler JP, Sneddon SL, and Brain JD: Cough. In: Macklem PT, Mead J (eds.), Handbook of Physiology, The Respiratory System. American Physiological Society, Be-thesda, MD; pp. 315-336, 1986.
6. Widdicombe JG: Airway liquid: a barrier to drug diffusion? Eur Respir J. 1997;10:2194-2197.
7. Edsbäcker S, and Johansson CJ: Airway selectivity: an up-date of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids. Basic Clin Pharmacol Tox-icol. 2006;98:523-536.
8. Sanders NN, De Smedt SC, Van Rompaey E, Simeons P, De Baets F, and Demeester J: Cystic fibrosis sputum\a barrier to the transport of nanospheres. Am J Resp Crit Care Med. 2000;162:1905-1911.
9. Khanvilkar K, Donovan MD, and Flanagan DR: Drug trans-fer through mucus. Adv Drug Deliv Rev. 2001;48:173-193.
10. Arora D, and Sakagami M: Kinetic assessment of aerosol particle dissolution and membrane permeation for testing commercial inhaler products. AAPS J. 2007;9:W5241.
11. Arora D, and Sakagami M: In vitro lung epithelial cell monolayer-based assessment of anti-inflammatory re-sponse of inhaled corticosteroids and deposition: the im-portance of dissolution. AAPS J. 2008;10:T2169.
12. Tolman JA, and Williams RO: Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solu-bilization on pharmacokinetic properties. Drug Dev Ind Pharm. [Epub ahead of print]. PMID: 19640248.
13. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, and Weers JG: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volun-teers. Chest. 2003;124:360-363.
14. Sakagami M: Insulin disposition in the lung following oral inhalation in humans: a meta-analysis of its pharmacoki-netics. Clin Pharmacokinet. 2004;43:539-552.
15. Clark A, Kuo M, Newman S, Hirst P, Pitcairn G, and Pickford M: A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon cal-citonin. Pharm Res. 2008;25:1583-1590.
16. Davies NM, and Feddah MR: A novel method for assessing dissolution of aerosol inhaler products. Int J Pharm. 2003; 255:175-187.
17. Freiwald M, Valotis A, Kirschbaum A, McClellan M, Mürdter T, Fritz P, Friedel G, Thomas M, and Högger P: Monitoring the initial pulmonary absorption of two different beclomethasone dipropionate aerosols employ-ing a human lung reperfusion model. Respir Res. 2005; 6:21.
18. Chowhan ZT, and Amaro AA: Pulmonary absorption studies utilizing in situ rat lung model: designing dosage regimen for bronchial delivery of new drug entities. J Pharm Sci. 1976;65:1669-1672.
19. Yang JZ, Young AL, Chiang PC, Thurston A, and Pretzer DK: Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci. 2008;97:4869-4878.
20. Gray VA, Hickey AJ, Balmer P, Davies NM, Dunbar C, Foster TS, Olosson BL, Sakagami M, Shah VP, Smurthwaite MJ, Veranth JM, and Zaidi K: The inhalation ad hoc advi-sory panel for the USP performance tests of inhalation dosage forms. Pharmacopeial Forum. 2008;34:1068-1074.
21. Sakagami M, Byron PR: Respirable microspheres for inha-lation: the potential of manipulating pulmonary disposition for improved therapeutic efficacy. Clin Pharmacokinet. 2005;44:263-277.
22. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Lunts A, Kreyling W, and Cox C: Extrapulmonary trans-location of ultrafine carbon particles following whole-body inhalation exposure of rats. J Toxicol Environ Health A. 2002;65:1531-1543.
23. Oberdörster G, Ferin J, and Lehnert BE: Correlation be-tween particle size, in vivo particle persistence, and lung injury. Environ Health Perspect. 1994;102:173-179.
24. Geiser M, Rothen-Rutishauser B, Kapp N, Schürch S, Kreyling W, Schulz H, Semmler M, Im Hof V, Heyder J, and Gehr P: Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect. 2005;113:1555-1560.
25. Braeckmans K, Peeters L, Sanders NN, De Smedt SC, and Demeester J: Three-dimensional fluorescence recovery after photobleaching with the confocal scanning laser micro-scope. Biophys J. 2003;85:2240-2252.
26. Brain J: Inhalation, deposition, and fate of insulin and other therapeutic proteins. Diabetes Technol Ther. 2007;9:S4-S15.
27. Dawson M, Wirtz D, and Hanes J: Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J Biol Chem. 2003;278:50393-50401.
28. Randall SH, and Boucher RC: Effective mucus clearance is essential for respiratory health. Am J Resp Cell Mol Biol. 2006;35:20-28.
29. Kaliner M, Shelhamer JH, Borson B, Nadel J, Patow C, and Marom Z: Human respiratory mucus. Am Rev Respir Dis. 1986;134:612-621.
30. Schürch S, Geiser M, Lee MM, and Gehr P: Particles at the airway interfaces of the lung. Colloids Surfaces B: Bioin-terfaces. 1999;15:339-353.
31. Geiser M, Schürch S, and Gehr P: Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J Appl Physiol. 2003;94: 1793-1801.
32. Sakagami M, Sakon K, Kinoshita W, and Makino Y: En-hanced pulmonary absorption following aerosol adminis-tration of mucoadhesive powder microspheres. J Control Release. 2001;77:117-129.
33. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, and Ka-washima Y: Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junc-tions. J Control Release. 2005;102:373-381.
34. Sanders NN, Van Rompaey E, De Smedt SC, and Demee-ster J: On the transport of lipoplexes through cystic fibrosis sputum. Pharm Res. 2002;19:451-456.
35. Carrabino S, Di Gioia S, Copreni E, and Conese M: Serum albumin enhanced polyethyleneimine-mediated gene de-livery to human respiratory epithelial cells. J Gene Med. 2005;7:1555-1564.
36. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle MP, and Hanes J: The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials. 2009;30: 2591-2597.
37. Patton JS: Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev. 1996;19:3-36.
38. Kim KJ, and Malik A: Protein transport across the lung epithelial barrier. Am J Physiol. 2003;284:L247-L259.
39. Siekmeier R, and Scheuch G: Inhaled insulin\does it be-come reality? J Physiol Pharmacol. 2008;59:81-113.
40. Yamahara H, Lehr CM, Lee VH, and Kim KJ: Fate of insulin during transit across rat alveolar epithelial cell monolayers. Eur J Pharm Biopharm. 1994;40:294-298.
41. Bur M, Huwer H, Lehr CM, Hagen N, Guldbrandt M, Kim KJ, and Ehrhardt C: Assessment of transport rates of proteins and peptides across primary human alveolar epithelial cell monolayers. Eur J Pharm Sci. 2006;28:196-203.
42. Ducreux J, and Vanbever R: Crucial biopharmaceutical is-sues facing macromolecular candidates for inhalation: the role of macrophages in pulmonary protein clearance. Re-spir Drug Deliv Eur. 2007;2007:31-41.
43. Lombry C, Edwards DA, Preat V, and Vanbever R: Al-veolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am J Physiol. 2004;286: L1002-L1008.
44. Berg JT, Lee ST, Thepen T, Lee CY, and Tsan MF: Depletion of alveolar macrophages by liposome-encapsulated di-chloromethylene diphosphonate. J Appl Physiol. 1993;74: 2812-2819.
45. Pinto AJ, Stewart D, van Rooijen N, and Morahan PS: Se-lective depletion of liver and splenic macrophages using liposomes encapsulating the drug dichloromethylene di-phosphonate: effects on antimicrobial resistance. J Leukoc Biol. 1991;49:579-586.
46. Kim KJ, Fandy TE, Lee VH, Ann DK, Borok Z, and Cran-dall ED: Net absorption of IgG via FcRn-mediated transcytosis across rat alveolar epithelial cell monolayers. Am J Physiol. 2004;287:L616-L622.
47. Allavena P, Chieppa M, Monti P, and Piemonti L: From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit Rev Immun. 2004;24:179-192.
48. Janeway CA, Travers P, Walport M, Shlomchik MJ: Im-munobiology: The Immune System in Health and Disease, 6th ed. Garland Publishing, New York; 2005.
49. Wright JR: Immunomodulatory functions of surfactant. Physiol Rev. 1997;77:931-962.
50. Wikstrom ME, and Stumbles PA: Mouse respiratory tract dendritic cell subsets and the immunological fate of inhaled antigens. Immunol Cell Biol. 2007;85:182-188.
51. Lombry C, Louahed J, Ucakar B, Renauld JC, Preat V, and Vanbever R: Alveolar macrophages inhibit the immune response to pulmonary antigen delivery. J Aerosol Med. 2005;18:114-115.
52. Holt PG: Regulation of immunological homeostasis in the respiratory tract. Nat Rev Immunol. 2008;8:142-152.
53. Chelen CJ, Fang Y, Freeman GJ, Secrist H, Marshall JD, Hwang PT, Frankel LR, DeKruyff RH, and Umetsu DT: Human alveolar macrophages present antigen ineffectively du the defective expression of B7 costi-maultory cell surface molecules. J Clin Invest. 1995;95: 1415-1421.
54. Holt PG, Oliver J, Bilyk N, McMenamin CH, McMenamin PG, Kraal G, and Thepen T: Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med. 1993; 177:397-407.
55. Lambrecht BN: Alveolar macrophage in the driver's seat. Immunity. 2006;24:366-368.
56. Reddy ST, Swartz MA, and Hubbell JA: Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006;27:573-579.
57. Endter S, Francombe D, Ehrhardt C, and Gumbleton M: RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol. 2009;61:583-591.
58. Bosquillon C. Drug transporters in the lung\do they play a role in the biopharmaceutics of inhaled drugs? J Pharm Sci [Epub ahead of print] PMID: 19950388.
59. Van der Deen M, de Vries EG, Timens W, Scheper RJ, Timmer-Bosscha H, and Postma DS: ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res. 2005;6:59.
60. Gumbleton M, Al-Jayyoussi G, Francombe D, Morris CJ, and Smith MW: Spatial expression and functionality of drug transporters in intact lung: areas for further investi-gation in pulmonary drug transporter research. J Aerosol Med Pulm Drug Deliv. (in press).
61. Pajeva IK, and Wiese M: Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explana-tion of structural variety (hypothesis). J Med Chem. 2002; 45:5671-5686.
62. Raub TJ: P-glycoprotein recognition of substrates and cir-cumvention through rational drug design. Mol Pharma-ceut. 2006;3:3-25.
63. Stouch TR, and Gudmundsson O: Progress in understand-ing the structure-activity relationships of P-glycoprotein. Adv Drug Deliv Rev. 2002;54:315-328.
64. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, and Klaassen CD: Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos. 2002;30:838-844.
65. Campbell L, Abulrob AN, Kandalaft LE, Plummer S, Hol-lins AJ, Gibbs A, and Gumbleton M: Constitutive expres-sion of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures. J Pharmacol Exp Ther. 2003;304:441-452.
66. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, and Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38:1277-1287.
67. Lechapt-Zalcman E, Hurbain I, Lacave R, Commo F, Urban T, Antoine M, Milleron B, and Bernaudin JF: MDR1-Pgp 170 expression in human bronchus. Eur Respir J. 1997;10:1837-1843.
68. Van der Valk P, van Kalken CK, Ketelaars H, Broxter-man HJ, Scheffer G, Kuiper CM, Tsuruo T, Lankelma J, Meijer CJ, Pinedo HM, and Scheper RJ: Distribution of multi-drug resistance-associated P-glycoprotein in nor-mal and neoplastic human tissues. Ann Oncol. 1990;1: 56-64.
69. Scheffer GL, Pijnenborg AC, Smit EF, Muller M, Postma DS, Timens W, van der Valk P, de Vries EG, and Scheper RJ: Multidrug resistance related molecules in human and murine lung. J Clin Pathol. 2002;55:332-339.
70. Endter S, Becker U, Daum N, Huwer H, Lehr CM, Gum-bleton M, and Ehrhardt C: P-glycoprotein (MDR1) func-tional activity in human alveolar epithelial cell monolayers. Cell Tissue Res. 2007;328:77-84.
71. Tronde A, Norden B, Marchner H, Wendel AK, Lennernas H, and Bengtsson UH: Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorp-tion relationships and physicochemical profiling of inhaled drugs. J Pharm Sci. 2003;92:1216-1233.
72. Tronde A, Norden B, Jeppsson AB, Brunmark P, Nilsson E, Lennernas H, and Bengtsson UH: Drug absorption from the isolated perfused rat lung\correlations with drug physicochemical properties and epithelial permeability. J Drug Target. 2003;11:61-74.
73. Manford F, Riffo-Vasquez Y, Spina D, Page CP, Hutt AJ, Moore V, Johansson F, and Forbes B: Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein sub-strate, in mdr1a-deficient and mdr1a-competent mice. J Pharm Pharmacol. 2008;60:1305-1310.
74. Madlova M, Bosquillon C, Asker D, Dolezal P, and Forbes B: In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity. J Pharm Phar-macol. 2009;61:293-301.
75. Francombe D, Taylor G, Taylor S, Somers G, Edwards CD, and Gumbleton M: Functional role of P-gp efflux in limit-ing pulmonary drug absorption within an intact lung: ap-plication of an isolated perfused rat lung model. Respir Drug Deliv. 2008:461-464.
76. Deeley RG, Westlake C, and Cole SP: Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006;86:849-899.
77. Gradhand U, and Kim RB: Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev. 2008;40:317-354.
78. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, and Scheper RJ: Tissue distribution of the mul-tidrug resistance protein. Am J Pathol. 1996;148:1237-1247.
79. Brechot JM, Hurbain I, Fajac A, Daty N, and Bernaudin JF: Different pattern of MRP localization in ciliated and basal cells from human bronchial epithelium. J Histochem Cy-tochem. 1998;46:513-517.
80. Robey RW, To KK, Polgar O, Dohse M, Fetsch P, Dean M, and Bates SE: ABCG2: a perspective. Adv Drug Deliv Rev. 2009;61:3-13.
81. Fetsch PA, Abati A, Litman T, Morisaki K, Honjo Y, Mittal K, and Bates SE: Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 2006;235:84-92.
82. Koepsell H, Lips K, and Volk C: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227-1251.
83. Lips KS, Volk C, Schmitt BM, Pfeil U, Arndt P, Miska D, Ermert L, Kummer W, and Koepsell H: Polyspecific cation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005;33:79-88.
84. Horvath G, Schmid N, Fragoso MA, Schmid A, Conner GE, Salathe M, and Wanner A: Epithelial organic cation trans-porters ensure pH-dependent drug absorption in the air-way. Am J Respir Cell Mol Biol. 2007;36:53-60.
85. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, and Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease (COPD) drug, is mediated by organic cation/carnitine transporters in human bron-chial epithelial cells: implications for carrier-mediated pul-monary absorption. Mol Pharm. 2010;7:187-195.
86. Ehrhardt C, Kneuer C, Bies C, Lehr CM, Kim KJ, and Ba-kowsky U: Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulm Pharmacol Ther. 2005;18:165-170.
87. Anzai N, Kanai Y, and Endou H: Organic anion transporter family: current knowledge. J Pharmacol Sci. 2006;100:411-426.
88. Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, and Slatter JG: Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a re-source for investigations into drug disposition. Xenobiotica. 2006;36:963-988.
89. Hagenbuch B, and Meier PJ: The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003;1609:1-18.
90. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, and Tsuji A: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273:251-260.
91. Groneberg DA, Eynott PR, Doring F, Dinh QT, Oates T, Barnes PJ, Chung KF, Daniel H, and Fischer A: Distribution and function of the peptide transporter PEPT2 in normal and cystic fibrosis human lung. Thorax. 2002;57:55-60.
92. Scheuch G, and Siekmeier R: Novel approaches to enhance pulmonary delivery of peptides and proteins. J Physiol Pharmacol. 2007;58:615-625.
93. Patton JS, Bukar JG, and Eldon MA: Clinical pharmacoki-netics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43:781-801.
94. Sweeney TD, Brain JD, Tryka AF, and Godleski JJ: De-position of particles in hamsters with pulmonary fibrosis. Am Rev Respir Dis. 1983;128:138-143.
95. Sweeney TD, Brain JD, Leavitt SA, and Godleski JJ: Em-physema alters the deposition pattern of inhaled particles in hamsters. Am J Pathol. 1987;128:19-28.
96. Sweeney TD, Skornik WA, Brain JD, Hatch V, and Godleski JJ: Chronic bronchitis alters the pattern of deposition in the lung. Am J Respir Crit Care Med. 1995;151:482-488.
97. Brain JD, Sweeney TD, Tryka AF, Skornik WA, and God-leski JJ: Effects of pulmonary fibrosis on aerosol deposition in hamsters. J Aerosol Sci. 1984;15:217-218.
98. Tryka AF, Sweeney TD, Brain JD, and Godleski JJ: Pulmon-ary fibrosis alters short-term clearance of an inhaled sub-micrometric aerosol. Am Rev Respir Dis. 1985;132:606-611.
99. Bondesson E, Bengtsson T, Nilsson LE, and Wollmer P: Site of deposition and absorption of inhaled hydrophilic sol-utes. Respir Drug Deliv. 2006;461-464.
100. Palmer LB, Smaldone GC, Chen JJ, Baram DM, Duan T, Monteforte M, Varela M, Tempone MK, O'Riordan T, Daroowalla F, and Richman P: Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med. 2008;36:2008-2013.
101. Petersen AH, Kohler G, Korsatko S, Wutte A, Wonisch M, Mautner A, Ronn BB, Clauson P, Laursen T, Wollmer P, and Pieber TR: The effect of exercise on the absorption of inhaled human insulin in healthy volunteers. Br J Clin Pharmacol. 2008;65:165-171.
102. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, and Nukiwa T: Hetero-geneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;169:1203-1208.
103. Souza CA, Muller NL, Flint J, Wright JL, and Churg A: Idiopathic pulmonary fibrosis: spectrum of high-resolution CT findings. Am J Roentgenol. 2005;185:1531-1539.
104. Gaine S: Pulmonary hypertension. JAMA. 2000;284:3160-3168.
105. McGoon MD, and Kane GC: Pulmonary hypertension: di-agnosis and management. Mayo Clin Proc. 2009;84:191-207.
106. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, and Voelkel NF: The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 2008;178:558-564.
107. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, and Seyfarth HJ: Inhaled iloprost for the control of pulmo-nary hypertension. Vasc Health Risk Manage. 2009;5: 465-474.
108. Godoy MC, and Naidich DP: Review: subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assess-ment and management. Radiology. 2009;253:606-622.
109. Latimer P, Menchaca M, Snyder RM, Yu W, Gilbert BE, Sanders BG, and Kline K: Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases. Exp Biol Med. 2009;234:1244-1252.
110. Bosch F, and Rosich L: The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology. 2008;82:171-179.
111. Maeda H, Bharate GY, and Daruwalla J: Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharmacol. 2009;71:409-419.
112. Wei YH, Xu LZ, Shen Q, and Li FZ: Microdialysis: a tech-nique for pharmacokinetic-pharmacodynamic studies of oncological drugs. Curr Pharm Biotechnol. 2009;10:631-640.
113. Kobayashi H: Airway biofilms: Implications for pathogen-esis and therapy of respiratory tract infections. Treat Respir Med. 2005;4:241-253.
114. Liu YC, and Post JC: Biofilms in pediatric respiratory and related infections. Curr Allergy Asthma Rep. 2009;9:449-455.
115. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, and Per-kins WR: Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudo-monas aeruginosa lung infections. J Antimicrob Chemother. 2008;61:859-868.
116. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, and Hudson LD: Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685-1693.
117. Calfee CS, and Matthay MA: Nonventilatory treatments for acute lung injury and ARDS. Chest. 2007;131:913-920.
118. Roux J, Carles M, Koh H, Goolaerts A, Ganter MT, Che-sebro BB, Howard M, Houseman BT, Finkbeiner W, Shokat KM, Paquet AC, Matthay MA, and Pittet JF: TGF-{beta}1 inhibits CFTR-dependent cAMP-stimulated alveolar epi-thelial fluid transport via a PI3K-dependent mechanism. J Biol Chem. 2009 [Epub ahead of print] PMID: 19996317.
119. Glenny RW, Bernard SL, and Lamm WJ: Hemodynamic effects of 15-micron diameter microspheres on the rat pul-monary circulation. J Appl Physiol. 2000;89:499-504.
120. Gill DR, Davies LA, Pringle IA, and Hyde SC: The devel-opment of gene therapy for diseases of the lung. Cell Mol Life Sci. 2004;61:355-368.
121. Griesenbach U, and Alton EW: Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev. 2009;61:128-139.
122. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, East-man SJ, Cheng SH, Smith AE, Meeker D, and Geddes DM: Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet. 1999;353:947-954.
123. Perricone MA, Morris JE, Pavelka K, Plog MS, O'Sullivan BP, Joseph PM, Dorkin H, Lapey A, Balfour R, Meeker DP, Smith AE, Wadsworth SC, St George JA: Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum Gene Ther. 2001;12:1383-1394.
124. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, and Heald AE: Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007;18:726-732.
125. Coates AL, Tipples G, Leung K, Gray M, and Louca E: How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine. 2006;24: 1578-1585.
126. Davies LA, Hannavy K, Davies N, Pirrie A, Coffee RA, Hyde SC, and Gill DR: Electrohydrodynamic comminution: a novel technique for the aerosolisation of plasmid DNA. Pharm Res. 2005;22:1294-1304.
127. Rochat T, and Morris MA: Gene therapy for cystic fibrosis by means of aerosol. J Aerosol Med. 2002;15:229-235.
128. McLachlan G, Baker A, Tennant P, Gordon C, Vrettou C, Renwick L, Blundell R, Cheng SH, Scheule RK, Davies L Painter H, Coles RL, Lawton AE, Marriott C, Gill DR, Hyde SC, Griesenbach U, Alton EW, Boyd AC, Porteous DJ, and Collie DD: Optimizing aerosol gene delivery and expres-sion in the ovine lung. Mol Ther. 2007;15:348-354.
129. Worgall S, Leopold PL, Wolff G, Ferris B, Van Roijen N, and Crystal RG: Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epi-thelial surface of the respiratory tract. Hum Gene Ther. 1997;8:1675-1684.
130. Sumner-Jones SG, Gill DR, and Hyde SC: Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airway. J Virol. 2007;81:12360-12367.
131. Van Ginkel FW, Liu C, Simecka JW, Dong JY, Greenway T, Frizzell RA, Kiyono H, McGhee JR, and Pascual DW: In-tratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to ad-enovirus and beta-galactosidase. Hum Gene Ther. 1995;6:895-903.
132. Sinn PL, Burnight ER, and McCray PB: Progress and prospects: prospects of repeated pulmonary administration of viral vectors. Gene Ther. 2009;16:1059-1065.
133. Sinn PL, Arias AC, Brogden KA, and McCray PB: Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol. 2008;82:10684-10692.
134. Dorin JR: Development of mouse models for cystic fibrosis. J Inherit Metab Dis. 1995;18:495-500.
135. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, Rogan MP, Pezzulo AA, Karp PH, Itani OA, Kabel AC, Wohlford-Lenane CL, Davis GJ, Hanfland RA, Smith TL, Samuel M, Wax D, Murphy CN, Rieke A, Whitworth K, Uc A, Starner TD, Brogden KA, Shilyansky J, McCray PB, Zabner J, Prather RS, and Welsh MJ: Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science. 2008;321:1837-1841.
136. Xia W, Pinto CE, and Kradin RL: The antigen-presenting activities of Ia\+dendritic cells shift dynamically from lung to lymph node after and airway challenge with soluble antigen. J Exp Med. 1995;181:1275-1283.